So unlucky! Right before the good news about Moderna's cancer vaccine, JPMorgan analyst Jessica Fye maintained a sell rating for the company with a target price of $40. But after tonight's market open, it surged to a high of $160. ORTEX estimates short sellers are facing approximately $4.8 billion in paper losses.